Trial Profile
A Phase II, Open Label, Multicenter Trial of Venetoclax (ABT-199/GDC-0199) as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma Not Otherwise Specified (PTCL-NOS), Angioimmunoblastic T-cell Lymphoma (AITL) and Other Nodal T-cell Lymphomas of T-follicular Helper Origin (TFH)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Jul 2023
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Therapeutic Use
- Acronyms FIL_VERT
- 05 Jul 2023 Status changed from active, no longer recruiting to discontinued.
- 20 Dec 2022 Planned End Date changed from 2 Dec 2022 to 2 Feb 2023.
- 26 Nov 2021 Planned End Date changed from 31 May 2021 to 2 Dec 2022.